期刊
BRAIN IMAGING AND BEHAVIOR
卷 6, 期 1, 页码 1-15出版社
SPRINGER
DOI: 10.1007/s11682-011-9136-1
关键词
Alzheimer's disease; ADNI; Pathway-based gene analysis; PiB-PET; Endophenotype; Voxel-based analysis
类别
资金
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health (NIH) [U01 AG024904]
- National Institute on Aging (NIA)
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- NIH [U01 AG024904, P30 AG010129, K01 AG030514, NIBIB R03 EB008674, NIBIB R03 EB008674S1, UL1RR025761, NLM T15LM07117, U01 HL086528, R01 MH078151, AG027859, AG027984, AG024904, P01 NS15655, R01 HL079540, R01 DA022520, R01 DA016423, AG018402, NIA R01-AG11378, U01 AG024904-01, P41 RR023953, R01 AG10897, P01 AG19724, P50 AG23501, R24 RR021992, R01 NS031966, P01 AG012435, R01 CA101318, R01 AG19771, RC2 AG036535, P30 AG10133-18S1, U01 AG032984]
- Alzheimer's Disease Genetics Consortium (ADGC) [U01 AG032984]
- National Cell Repository for AD (NCRAD) [U24 AG21886]
- NIA
- NIH (CTSI) [TL1 RR025759]
- NIAAA [R21AA016901, NIDA R03DA024774, NIAAA R01AA017661, NIA P30AG010133-20]
- Indiana State Department of Health [PI]
- IUPUI
- Indiana CTSI Clinical Research Center [UL RR025761]
- NIH (NIA) [U01 AG032984, 5U24AG021886, R01 AR047822, R01 NS037167, N01NS32357, U01AA014809, R01 CA141668, P01 AG018397, NCRR U24 RR021992, NCIRE AG036535]
- Families of Spinal Muscular Atrophy
- Muscular Dystrophy Association
- HP Therapeutics Foundation
- CHDI Foundation
- AstraZeneca
- Bioline
- Bristol
- Myers-Squibb
- Cortex Pharmaceuticals, Inc.
- Dainippon Sumitomo Pharma
- Janssen
- Novartis
- Merck Serono
- Pfizer Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Roche
- Minister Pharmaceuticals plc
- Transdisciplinary Imaging Genetics Center (TIGC) [P20 RR020837]
- NIH/NINDS [R01 NS059873]
- Arizona Alzheimer's Consortium
- Arizona Science Foundation
- Arizona Alzheimer's Research Center
- Alzheimer's Association
- Elan Corporation
- GE Healthcare
- Bayer-Schering Pharma
- IBA
- Takeda Pharmaceutical Company Limited
- Neuroptix Corporation
- US Department of Energy
- Anonymous Foundation
- GE Healthcare (amyloid imaging agents for brain applications)
- Neuroptix Corporation (amyloid imaging agents for eye applications)
- Pfizer, Inc.
- Mayo Foundation
- Nestl
- Kenes International
- Merck and Co.
- Avid Radiopharmaceuticals Inc.
- US Department of Defense
- Veterans Administration
- State of California
- Eli Lilly and Company
- Siemens AG
- Welch Allyn Inc
- Indiana Economic Development Corporation (IEDC)
- Foundation for the NIH
Amyloid imaging with [(11) C]Pittsburgh Compound-B (PiB) provides in vivo data on plaque deposition in those with, or at risk for, Alzheimer's disease (AD). We performed a gene-based association analysis of 15 quality-controlled amyloid-pathway associated candidate genes in 103 Alzheimer's Disease Neuroimaging Initiative participants. The mean normalized PiB uptake value across four brain regions known to have amyloid deposition in AD was used as a quantitative phenotype. The minor allele of an intronic SNP within DHCR24 was identified and associated with a lower average PiB uptake. Further investigation at whole-brain voxel-wise level indicated that non-carriers of the minor allele had higher PiB uptake in frontal regions compared to carriers. DHCR24 has been previously shown to confer resistance against beta-amyloid and oxidative stress-induced apoptosis, thus our findings support a neuroprotective role. Pathway-based genetic analysis of targeted molecular imaging phenotypes appears promising to help elucidate disease pathophysiology and identify potential therapeutic targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据